Document is current
Any future updates will be listed below
-
Authors
Shapira, Tirosh
Monreal, I. Abrrey https://orcid.org/0000-0003-0521-9063
Dion, Sébastien P. https://orcid.org/0000-0002-8961-0782
Buchholz, David W. https://orcid.org/0000-0001-8874-6648
Imbiakha, Brian
Olmstead, Andrea D. https://orcid.org/0000-0002-1110-1291
Jager, Mason https://orcid.org/0000-0001-6036-9895
Désilets, Antoine https://orcid.org/0000-0001-5081-5564
Gao, Guang
Martins, Mathias https://orcid.org/0000-0002-8290-5756
Vandal, Thierry
Thompson, Connor A. H.
Chin, Aaleigha
Rees, William D. https://orcid.org/0000-0002-3171-3068
Steiner, Theodore
Nabi, Ivan Robert https://orcid.org/0000-0002-0670-0513
Marsault, Eric
Sahler, Julie
Diel, Diego G.
Van de Walle, Gerlinde R. https://orcid.org/0000-0002-2064-8029
August, Avery https://orcid.org/0000-0003-4968-3415
Whittaker, Gary R.
Boudreault, Pierre-Luc https://orcid.org/0000-0002-2032-7970
Leduc, Richard https://orcid.org/0000-0001-6854-8003
Aguilar, Hector C. https://orcid.org/0000-0001-6879-8360
Jean, François https://orcid.org/0000-0002-6148-7460
- License Information
-
More Information
Article History
Received: 14 May 2021
Accepted: 18 March 2022
First Online: 28 March 2022
Competing interests
: P.-L.B. and R.L. are inventors on patent applications (US9365853B2 and US10988505B2) that cover matriptase and other type II transmembrane serine proteases inhibitors for treating and preventing viral infections, respiratory disorders, inflammatory disorders, pain disorders, tissue disorders, hyperproliferative disorders, and disorders associated with iron overload. The remaining authors declare that they have no competing interests.
